原肾与移植肾补体3肾小球病(C3G)综述
本文综述补体3肾小球病(C3G)的病理生理、预后及治疗,涵盖致密沉积物病和C3肾小球肾炎两种亚型。C3G由替代途径过度激活驱动,遗传变异和/或自身抗体是常见原因,移植后复发风险高且预后差。传统支持治疗及终端补体级联靶向治疗改善肾脏生存有限,靶向替代途径过度激活的新兴疗法展现疾病修饰潜力。
要点
- C3G由补体替代途径过度激活驱动,遗传变异和/或自身抗体是常见病因。
- 移植后C3G复发风险高,复发者预后差、移植物丢失率高。
- 传统支持治疗及终端补体级联靶向治疗改善肾脏生存有限,靶向替代途径的新兴疗法有前景。
核心结论
- C3G是替代途径过度激活介导的罕见肾脏病,移植后复发风险高且预后差。
- 传统支持治疗及终端补体级联靶向治疗改善肾脏生存有限,靶向替代途径过度激活的新兴疗法展现疾病修饰潜力。
研究设计与样本
- 综述,总结原肾及移植后复发C3G的病理生理、预后和治疗现状。
主要发现
- C3G包括致密沉积物病和C3肾小球肾炎两种亚型,均导致肾小球C3沉积、进行性肾功能不全及肾衰竭。
- C3G的病理生理及替代途径过度激活常由遗传变异和/或获得性自身抗体驱动。
- 这些系统性驱动因素可影响原肾和移植肾,C3G与同种异体移植物高复发风险相关。
- 移植后C3G复发预后特别差,导致高移植物丢失率。
- 针对原肾及移植后复发C3G的支持治疗及靶向终端补体级联下游的治疗改善肾脏生存获益有限,而靶向替代途径过度激活的新兴疗法展现更有望的疾病修饰作用。
临床怎么用
- 临床需认识C3G的替代途径过度激活机制及遗传/自身抗体驱动因素,关注原肾和移植肾受累。
- 移植后应警惕C3G复发,复发者预后差、移植物丢失率高。
- 传统支持治疗及终端补体级联靶向治疗改善肾脏生存有限,可关注靶向替代途径过度激活的新兴疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Complement 3 glomerulopathy (C3G) is a rare complement-mediated kidney disease characterized by overactivation of the alternative pathway (AP). C3G encompasses 2 subtypes, dense deposit disease and C3 glomerulonephritis, both of which lead to C3 deposition in the glomeruli, progressive kidney dysfunction, and, ultimately, kidney failure. The pathophysiology of C3G and the underlying complement AP overactivation are often driven by genetic variants and/or acquired autoantibodies. These systemic drivers can affect native and transplanted kidneys; thus, C3G is associated with a high risk of recurrence in allografts. Recurrence of C3G in posttransplant kidneys has a particularly poor prognosis and leads to a high rate of graft loss. Therapeutic strategies for native and posttransplant recurrent C3G that are largely supportive have shown limited benefit in improving kidney survival, as have therapies targeting the terminal complement cascade downstream of pathogenic AP overactivation. In contrast, emerging therapies that target AP overactivation are showing promise for more effective disease modification. In light of the evolving treatment landscape, this review provides an update on the current state of knowledge regarding the pathophysiology, prognosis, and treatment options for native and posttransplant recurrent C3G.
引用
- Praga M, Smith RJ, Bomback AS, et al. Complement 3 Glomerulopathy (C3G) in Native and Posttransplant Kidneys: A Review. Am J Kidney Dis. 2026. PMID: 41921739. doi:10.1053/j.ajkd.2025.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。